Diamyd Medical AB (OMX:DIAMB) emerged as a global biotechnology company as shareholders approved the acquisition of Nurel Therapeutics, Inc. at a General Assembly Meeting in Stockholm yesterday. The Pittsburgh, PA- based biotech adds significantly to Diamyd Medical’s pipeline for diabetes which now includes both a therapeutic vaccine for autoimmune type 1 and type 2 diabetes as well as therapies for diabetic pain. The merger is expected to close on Friday, December 16.
